193 related articles for article (PubMed ID: 15993339)
1. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin.
Hoke EM; Maylock CA; Shacter E
Free Radic Biol Med; 2005 Aug; 39(3):403-11. PubMed ID: 15993339
[TBL] [Abstract][Full Text] [Related]
2. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
[TBL] [Abstract][Full Text] [Related]
3. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
Xu X; Sutak R; Richardson DR
Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550
[TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis by iron depletion in the human breast cancer MCF-7 cell line and the 13762NF rat mammary adenocarcinoma in vivo.
Jiang XP; Wang F; Yang DC; Elliott RL; Head JF
Anticancer Res; 2002; 22(5):2685-92. PubMed ID: 12529982
[TBL] [Abstract][Full Text] [Related]
5. Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
Fister S; Schlotawa L; Günthert AR; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jan; 24(1):24-9. PubMed ID: 17943530
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs.
Gewirtz DA; Di X; Walker TD; Sawyer ST
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2232-8. PubMed ID: 16609039
[TBL] [Abstract][Full Text] [Related]
7. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
[TBL] [Abstract][Full Text] [Related]
8. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo.
Thangapazham RL; Singh AK; Sharma A; Warren J; Gaddipati JP; Maheshwari RK
Cancer Lett; 2007 Jan; 245(1-2):232-41. PubMed ID: 16519995
[TBL] [Abstract][Full Text] [Related]
9. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
[TBL] [Abstract][Full Text] [Related]
10. Regulation of breast cancer response to chemotherapy by fibulin-1.
Pupa SM; Giuffré S; Castiglioni F; Bertola L; Cantú M; Bongarzone I; Baldassari P; Mortarini R; Argraves WS; Anichini A; Menard S; Tagliabue E
Cancer Res; 2007 May; 67(9):4271-7. PubMed ID: 17483339
[TBL] [Abstract][Full Text] [Related]
11. Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231.
Aroui S; Brahim S; De Waard M; Bréard J; Kenani A
Cancer Lett; 2009 Nov; 285(1):28-38. PubMed ID: 19523755
[TBL] [Abstract][Full Text] [Related]
12. The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a comparison with desferrioxamine.
Gharagozloo M; Khoshdel Z; Amirghofran Z
Eur J Pharmacol; 2008 Jul; 589(1-3):1-7. PubMed ID: 18619590
[TBL] [Abstract][Full Text] [Related]
13. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma.
Djojosubroto MW; Chin AC; Go N; Schaetzlein S; Manns MP; Gryaznov S; Harley CB; Rudolph KL
Hepatology; 2005 Nov; 42(5):1127-36. PubMed ID: 16114043
[TBL] [Abstract][Full Text] [Related]
14. Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture.
Hershko C; Link G; Tzahor M; Kaltwasser JP; Athias P; Grynberg A; Pinson A
J Lab Clin Med; 1993 Sep; 122(3):245-51. PubMed ID: 8409700
[TBL] [Abstract][Full Text] [Related]
15. Differential enhancement of the anti-cancer effect of doxorubicin by Akt inhibitors on human breast cancer cells with differing genetic backgrounds.
Wang YA; Johnson SK; Brown BL; Dobson PR
Oncol Rep; 2009 Feb; 21(2):437-42. PubMed ID: 19148520
[TBL] [Abstract][Full Text] [Related]
16. Effect of stable inhibition of NRF2 on doxorubicin sensitivity in human ovarian carcinoma OV90 cells.
Manandhar S; Lee S; Kwak MK
Arch Pharm Res; 2010 May; 33(5):717-26. PubMed ID: 20512470
[TBL] [Abstract][Full Text] [Related]
17. Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma.
Brard L; Granai CO; Swamy N
Gynecol Oncol; 2006 Jan; 100(1):116-27. PubMed ID: 16203029
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1.
Hu M; Wang J; Chen P; Reilly RM
Bioconjug Chem; 2006; 17(5):1280-7. PubMed ID: 16984139
[TBL] [Abstract][Full Text] [Related]
19. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
[TBL] [Abstract][Full Text] [Related]
20. Tannic acid ameliorates doxorubicin-induced cardiotoxicity and potentiates its anti-cancer activity: potential role of tannins in cancer chemotherapy.
Tikoo K; Sane MS; Gupta C
Toxicol Appl Pharmacol; 2011 Mar; 251(3):191-200. PubMed ID: 21194538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
